Business Context and Reporting Period
This Form 8-K, dated December 30, 2019, reports the completion of a business combination between Gemphire Therapeutics Inc. (the "Company") and NeuroBo Pharmaceuticals, Inc. ("NeuroBo"). The transaction was structured as a reverse acquisition, with NeuroBo treated as the accounting acquirer. Following the merger, the Company changed its name to NeuroBo Pharmaceuticals, Inc. and its ticker symbol to "NRBO" on The Nasdaq Capital Market. The Company is a clinical-stage biotechnology firm focused on developing pharmaceuticals for neurodegenerative disorders.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, or cash flow figures for the combined entity within this text; such data is referenced in the Proxy Statement and will be filed in a subsequent amendment. However, the following capital structure and transaction metrics are disclosed:
- Post-Merger Capitalization: Approximately 15,588,849 shares of common stock outstanding immediately following the merger.
- Ownership Distribution: Former NeuroBo stockholders and optionholders own approximately 96.17% of the fully-diluted common stock; former Company stockholders own approximately 3.83%.
- Exchange Ratio: 1.1431 shares of Company common stock for each share of NeuroBo common stock.
- Reverse Stock Split: A 1-for-25 reverse stock split was effected prior to the merger closing.
- Debt Obligations: The Company paid a $350,000 success fee to Silicon Valley Bank (SVB) in connection with the merger, satisfying a contingent obligation from a previously prepaid term loan.
- Equity Incentives: 3,000,000 new shares reserved under the 2019 Equity Incentive Plan; 959,060 options and 40,568 warrants outstanding post-merger.
Material Changes Versus Prior Period
The filing details a fundamental transformation of the registrant:
- Corporate Identity: The legal name changed from Gemphire Therapeutics Inc. to NeuroBo Pharmaceuticals, Inc.
- Business Focus: The Company's primary business shifted from its prior operations to NeuroBo's clinical-stage biotechnology pipeline targeting neurodegenerative disorders.
- Accounting Treatment: The transaction is a reverse acquisition; historical financial statements will reflect NeuroBo as the accounting acquirer, necessitating a change in auditors from Ernst & Young LLP to BDO USA, LLP.
- Board Composition: The board was reconstituted to seven members, with six designees selected by NeuroBo and one by the former Company. Four former directors resigned.
- Executive Leadership: Former Gemphire executives (Dr. Gullans, Dr. Bisgaier, Mr. Reno) terminated employment and received severance. Dr. Jeong Gu (Richard) Kang was appointed as President and CEO effective January 1, 2020.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The Company expects to commence trading under the new ticker "NRBO" on December 31, 2019. The business strategy is now centered on NeuroBo's development of novel pharmaceuticals for neurodegenerative disorders.
Contingencies and Agreements:
- Contingent Value Rights (CVR): A CVR Agreement was entered into with former Company stockholders, the terms of which are detailed in the Proxy Statement.
- Success Fee: A $350,000 payment was made to SVB as a success fee triggered by the merger, a liability that survived the prepayment of the original term loan.
- Executive Compensation: New employment agreements and consulting arrangements were established for key NeuroBo personnel, including a monthly consulting fee of $29,750 for Dr. Mark Versavel.
Risks: The filing notes that unaudited pro forma financial information and interim financial statements of NeuroBo will be filed in an amendment within 71 days. The change in auditor is a standard consequence of the reverse acquisition structure.
Important Facts for Investor Verification
- Verify the unaudited pro forma financial information and NeuroBo's interim financial statements (to be filed in a subsequent amendment) to assess the combined entity's liquidity and burn rate.
- Review the full terms of the Contingent Value Rights (CVR) Agreement to understand potential future cash or equity obligations to former Gemphire shareholders.
- Confirm the status of NeuroBo's clinical pipeline and regulatory milestones, as the Company's future value is entirely dependent on these clinical-stage assets.
- Monitor the transition of the audit firm to BDO USA, LLP and the resulting impact on the 2019 fiscal year financial reporting.
- Check the vesting schedules and terms of the new 2019 Equity Incentive Plan and the assumed NeuroBo stock options.